Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as int… Read more
Arctic Bioscience AS (ABS) - Net Assets
Latest net assets as of June 2025: Nkr195.30 Million NOK
Based on the latest financial reports, Arctic Bioscience AS (ABS) has net assets worth Nkr195.30 Million NOK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr290.35 Million) and total liabilities (Nkr95.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr195.30 Million |
| % of Total Assets | 67.26% |
| Annual Growth Rate | 45.84% |
| 5-Year Change | 229.58% |
| 10-Year Change | N/A |
| Growth Volatility | 156.65 |
Arctic Bioscience AS - Net Assets Trend (2018–2024)
This chart illustrates how Arctic Bioscience AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arctic Bioscience AS (2018–2024)
The table below shows the annual net assets of Arctic Bioscience AS from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr210.73 Million | -18.50% |
| 2023-12-31 | Nkr258.56 Million | -10.00% |
| 2022-12-31 | Nkr287.28 Million | -10.38% |
| 2021-12-31 | Nkr320.55 Million | +401.34% |
| 2020-12-31 | Nkr63.94 Million | +0.07% |
| 2019-12-31 | Nkr63.90 Million | +191.95% |
| 2018-12-31 | Nkr21.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arctic Bioscience AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr210.73 Million | 100.00% |
| Total Equity | Nkr210.73 Million | 100.00% |
Arctic Bioscience AS Competitors by Market Cap
The table below lists competitors of Arctic Bioscience AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Charwood Energy SA
PA:ALCWE
|
$3.71 Million |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
$3.72 Million |
|
Silver Touch Technologies Limited
NSE:SILVERTUC
|
$3.72 Million |
|
Exploits Discovery Corp
OTCQX:NFLDF
|
$3.72 Million |
|
Panamax AG
F:ICP
|
$3.71 Million |
|
BAB Inc
OTCQB:BABB
|
$3.71 Million |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
$3.71 Million |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
$3.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arctic Bioscience AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 258,557,236 to 210,730,763, a change of -47,826,473 (-18.5%).
- Net loss of 47,932,964 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-47.93 Million | -22.75% |
| Other Changes | Nkr106.49K | +0.05% |
| Total Change | Nkr- | -18.50% |
Book Value vs Market Value Analysis
This analysis compares Arctic Bioscience AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.75x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Nkr0.90 | Nkr3.38 | x |
| 2019-12-31 | Nkr2.63 | Nkr3.38 | x |
| 2020-12-31 | Nkr2.63 | Nkr3.38 | x |
| 2021-12-31 | Nkr13.19 | Nkr3.38 | x |
| 2022-12-31 | Nkr11.79 | Nkr3.38 | x |
| 2023-12-31 | Nkr10.17 | Nkr3.38 | x |
| 2024-12-31 | Nkr8.31 | Nkr3.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arctic Bioscience AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -110.23%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.33x
- Recent ROE (-22.75%) is below the historical average (-16.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -7.81% | -6.88% | 0.55x | 2.07x | Nkr-3.90 Million |
| 2019 | -6.24% | -13.28% | 0.36x | 1.29x | Nkr-10.38 Million |
| 2020 | -35.33% | -110.21% | 0.22x | 1.46x | Nkr-28.98 Million |
| 2021 | -13.28% | -197.91% | 0.06x | 1.07x | Nkr-74.64 Million |
| 2022 | -11.84% | -99.28% | 0.10x | 1.14x | Nkr-62.75 Million |
| 2023 | -17.60% | -134.86% | 0.11x | 1.16x | Nkr-71.37 Million |
| 2024 | -22.75% | -110.23% | 0.16x | 1.33x | Nkr-69.01 Million |
Industry Comparison
This section compares Arctic Bioscience AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $42,629,145
- Average return on equity (ROE) among peers: -133.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arctic Bioscience AS (ABS) | Nkr195.30 Million | -7.81% | 0.49x | $3.71 Million |
| Aqua Bio Technology ASA (ABTEC) | $8.32 Million | -176.71% | 0.95x | $7.08 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $76.32 Million |
| Circa Group AS (CIRCA) | $41.74 Million | -16.77% | 0.13x | $3.57 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $16.90 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.19 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.31 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $432.13K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.63 Million |
| Thor Medical ASA (TRMED) | $140.52 Million | -314.06% | 1.11x | $48.68 Million |